Biocon Limited — Updates, 30-06-2025: Press Release

Biocon Biologics has supplied over 100 million cartridges of recombinant human insulin to Malaysia’s Ministry of Health, serving 345,000+ patients. Their Johor facility, developed with a USD 600 million investment, supports local manufacturing of a broad insulin portfolio, enhancing affordable diabetes care in Malaysia. This milestone reflects Biocon's commitment to insulin self-sufficiency and positions it among the top global players for rh-Insulin and Insulin Glargine. Biocon Biologics continues to scale access, having delivered 9.2 billion doses globally, strengthening its footprint in diabetes management across emerging and advanced markets.